Minhai COVID-19 vaccine

Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.

In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.

[1] Later, KCONVAC started phase II trials with 1,000 participants in China.

[3] In August 2021, KCONVAC started phase I trials with 84 participants in China.

[4] In September, KCONVAC started phase II trials with 480 participants in China.

Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.